New data backs promise of long-acting Sanofi insulin

December 3, 2013 6:11 AM

8 0

New data backs promise of long-acting Sanofi insulin

PARIS (Reuters) - An improved version of Sanofi's diabetes drug Lantus is better than the old one at controlling blood sugar levels and comes with fewer hypoglycemic events, new late-stage trial data showed on Tuesday.

The treatment is one of several drugs Sanofi is betting on to defend its No.2 spot on the world's $42 billion diabetes market as its superstar product Lantus, the world's most prescribed insulin, will lose patent protection by 2015.

Read more

To category page

Loading...